ABSTRACT
Objective@#To assess the effectiveness and safety of indomethacin in preventing post-endoscopic retrograd cholangiopancreatography pancreatitis(PEP) by rectal administration.@*Methods@#Retrieved from PubMed, Cochrane Library, CNKI, VIP, CBM and Wanfang database, randomized blinding placebo-controlled trails about indomethacin for preventing PEP by rectal administration were included from establishment to December 2017 and comprehensively evaluated.Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, assessed the risk bias of included studies, and then Meta-analysis was performed using the RevMan 5.3 software.@*Results@#A total of 8 RCTs involving 3240 patients were included.The results of Meta-analysis showed that indomethacin could reduce the incidence of PEP(OR=0.57, 95% CI: 0.45-0.73, P<0.00 001) and moderate or severe PEP(OR=0.51, 95% CI: 0.30-0.85, P=0.010). The adverse reactions of indomethacin was gastrointestinal bleeding, and there was no statistically significant difference between indomethacin and placebo(OR=0.63, 95% CI: 0.25-1.52, P=0.300).@*Conclusion@#Indomethacin is safe and effective in reducing the incidence of PEP by rectal administration.
ABSTRACT
Objective To assess the effectiveness and safety of indomethacin in preventing post-endoscopic retrograd cholangiopancreatography pancreatitis (PEP) by rectal administration.Methods Retrieved from PubMed,Cochrane Library,CNKI,VIP,CBM and Wanfang database,randomized blinding placebo-controlled trails about indomethacin for preventing PEP by rectal administration were included from establishment to December 2017 and comprehensively evaluated.Two reviewers independently screened literature according to the inclusion and exclusion criteria,extracted data,assessed the risk bias of included studies,and then Meta-analysis was performed using the RevMan 5.3 software.Results A total of 8 RCTs involving 3240 patients were included.The results of Meta-analysis showed that indomethacin could reduce the incidence of PEP(OR =0.57,95％ CI:0.45-0.73,P ＜ 0.00 001) and moderate or severe PEP(OR =0.51,95 ％ CI:0.30-0.85,P =0.010).The adverse reactions of i ndomethacin was gastrointestinal bleeding,and there was no statistically significant difference between indomethacin and placebo(OR =0.63,95％ CI:0.25-1.52,P =0.300).Conclusion Indomethacin is safe and effective in reducing the incidence of PEP by rectal administration.
ABSTRACT
Objective To study the effect of multi drug combination therapy of children allergic purpura.Methods 80 cases of children with Henoch Schonlein purpura in our hospital from May 2014 to May 2016 were selected,these children were randomly divided into methylprednisolone,cimetidine and loratadine treatment group(treatment group)and methylprednisolone treatment group(control group),40 cases in each groups,the clinical curative effects,rash regression time,joint pain relief time,abdominal pain relief time,hematochezia disappeared time,urine recovery time,hospitalization time,incidences of adverse reaction and recurrences of the two groups were statistically analyzed.Results The total treatment efficiency of the treatment group was 95％(38/40),which was significantly higher than the control group 70％(28/40),the difference was statistically significant(P<0.05),the rash regression,joint pain relief time,abdominal pain relief time,hospitalization time of the treatment group were significantly shorter than the control group(P<0.05),but the differences the stool disappear time,urine recovery time,incidences of adverse reactions,recurrence rate between the two groups were not significant.Conclusion The effect of multi drug combination therapy of children with allergic purpura is better than single drug alone,can shorten the time of disappearance of symptoms of patients,reduce hospital stay.
ABSTRACT
Objective From the point of view of pharmaceutical economics,to analyze and compare the clinical efficacy,safety,compliance and economic effect of three kinds of scheme:1.moxifloxacin,2.moxifioxacin combined with ambroxol,3.azithromycin combined with levofloxacin in the treatment of acute exacerbation of chronic bronchitis (AECB).Methods Retrieval Chinese joumal full-text database,Wanfang medical database and Chinese science and technology periodical full-text database,included three options for the treatment of AECB randomized controlled trial (RCT) literature,through the analysis of the data to make drug economics evaluation.Results The total effective rates of three programs were 94.92％,95.08％,94.90％,the difference was not statistically significant (P ＞ 0.05).The cost-effectiveness ratios were 213.34,536.40,61.22.Conclusion The efficacy of three treatment options is similar,azithromycin combined with levofloxacin has economic advantages.